Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  hormonotherapy
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Apalutamide treatment of locally advanced prostate cancer

100%
Palasik M.
OncoReview
|
2023
|
vol. 13
|
issue 1
31-32
EN
Prostate cancer is most commonly diagnosed cancer in men. The choice of treatment method depends on many factors: the patient’s age, other patient’s diseases, psychophysical status and expected survival time. Hormonotherapy plays very important role in patients with no possible radical treatment. New therapies apply in patients with castration-resistant metastatic prostate cancer. First registered drug in patients with biochemical progression without metastases is apalutamide.
2
Publication available in full text mode
Content available

The role of enzalutamide in the treatment of prostate cancer from the perspective of Polish oncologists

88%
Bal W., Gajda M.
OncoReview
|
2022
|
vol. 12
|
issue 2
45-49
EN
For several years, prostate cancer has remained the most common malignancy in male patients in Poland. A large number of patients combined with rising costs of therapy translate into a significant socio-economic burden. In a clinical oncologist’s practice, we usually deal with patients with advanced prostate cancer. Taking into account the poorer prognosis in advanced disease, development of new therapeutic options as well we their adequate selection is of paramount importance. Enzalutamide is one of the second-generation androgen axis inhibitors, which has the ability to overcome resistance to androgen deprivation therapy by inhibiting the androgen-DNA signalling on several levels. Its efficacy and safety had been proven in numerous phase II and phase III clinical studies and it has been registered by regulatory authorities in the United States and European Union in the treatment of mCRPC, mCSPC and nmCRPC. In this article selected issues related to the treatment of prostate cancer are discussed, with particular emphasis on the role of enzalutamide (including its mechanism of action, indications, efficacy and safety).
3
Publication available in full text mode
Content available

Typical variant of takotsubo cardiomyopathy in oncological patients. Two case reports and review of the literature

75%
Stępień K., Nowak K., Pasieka P., Warmuz K., Stępień A., Nessler J., Zalewski J., Stępień K., Nowak K., Pasieka P., Warmuz K., Stępień A., Nessler J., Zalewski J.
Folia Medica Cracoviensia
|
2020
|
vol. 60
|
issue 1
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.